News articles about Medifast (NYSE:MED) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medifast earned a news impact score of 0.21 on Accern’s scale. Accern also gave media stories about the specialty retailer an impact score of 45.8415378990124 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Medifast (NYSE MED) opened at $72.16 on Friday. Medifast has a twelve month low of $40.00 and a twelve month high of $74.78. The stock has a market cap of $851.70, a PE ratio of 35.37, a price-to-earnings-growth ratio of 1.80 and a beta of 0.50.
Medifast (NYSE:MED) last issued its earnings results on Tuesday, November 7th. The specialty retailer reported $0.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.04. Medifast had a net margin of 8.58% and a return on equity of 24.07%. The firm had revenue of $77.20 million for the quarter, compared to analysts’ expectations of $74.94 million. During the same quarter last year, the company posted $0.51 earnings per share. Medifast’s revenue was up 12.5% on a year-over-year basis. sell-side analysts anticipate that Medifast will post 2.17 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 8th. Shareholders of record on Friday, December 22nd will be issued a $0.48 dividend. The ex-dividend date is Thursday, December 21st. This represents a $1.92 dividend on an annualized basis and a yield of 2.66%. This is a boost from Medifast’s previous quarterly dividend of $0.32. Medifast’s dividend payout ratio (DPR) is currently 94.12%.
Several brokerages have recently commented on MED. DA Davidson increased their price target on shares of Medifast to $89.00 and gave the stock a “buy” rating in a research report on Friday, December 8th. Zacks Investment Research raised shares of Medifast from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a research report on Friday, November 10th. ValuEngine cut shares of Medifast from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Sidoti reaffirmed a “neutral” rating and set a $55.00 price target (up previously from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $74.33.
In other Medifast news, Director Glenn W. Welling sold 275,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $64.60, for a total value of $17,765,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Glenn W. Welling sold 250,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.00, for a total transaction of $16,250,000.00. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.
WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-medifast-med-share-price.html.
Medifast Company Profile
Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.